In this study, we utilize a Methylation Assay Kit designed explicitly for the Twist1/Vimentin gene (produced by Jiangsu MicroDiag Biomedicine Co., Ltd., China), intending to assess its diagnostic precision and clinical applicability in patients with bladder cancer. The gene discussed is VIM; the disease is urinary bladder cancer.